1. United States of America Stocks

  2. •

    Industrials

  3. •

    Electrical Equipment & Parts
MetaStat Inc

MetaStat Inc

MTST
MetaStat IncUS flagOther OTC
0.00
USD
- -
- -
5,877.00Market Cap
MetaStat Inc
MTST
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-4.63
-11.51
-2.83
-0.55
-2.25
-1.81
-3.8
-4.96
-3.3
-2.1
-0.6
-0.62
Basic EPS, GAAP
-1.88
-2.67
- -
-0.42
-1.21
-1.75
-1.68
-2.2
-1.81
-0.78
-0.51
-0.52
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4.61
-15
-17.82
-0.63
-2.63
-3.85
-7.6
-11.27
-12.87
-8.87
-5.44
-5.6
Book Value per Share
7.78
-2.45
-5.27
0.38
1.36
0.1
-1.47
0.15
-0.97
-0.94
-0.29
-0.29
Tangible Book Value per Share
- -
- -
- -
1
1
1
1
2
2
3
5
5
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-15,238.25
-15,238.25
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-2
-3
-5
-8
-5
-3
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-13,652.46
-13,652.46
Profit Margin (%)
- -
- -
- -
- -
1
- -
-2
- -
-2
-1
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
1
- -
-2
- -
-2
-3
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Aug'18
Nov'18
Feb'18
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
34
35
65

Working Capital

FRC

•

in mil. unless spec.
Aug'18
Nov'18
Feb'18
Total Current Assets
2
1
- -
Cash, Cash Equivalents & STI
2
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-243.28%
-512.4%
-44.59%
Free Cash Flow
- -
6.22%
19.15%
Net Income, GAAP
110.61%
18.29%
8.14%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
-97.01%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-1.18
-0.73
-0.72
- -
-3.3
2017
-1.08
-0.46
-0.45
- -
-2.1
2018
-0.06
-0.15
-0.21
- -
-0.6

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Well Shin Technology Co., Ltd. (3501.TW)
Sieyuan Electric Co., Ltd. (002028.SZ)
Shenzhen V&T Technologies Co., Ltd. (300484.SZ)
L&F Co., Ltd. (066970.KQ)
Ram Ratna Wires Limited (RAMRAT.NS)
Qingdao Hanhe Cable Co.,Ltd (002498.SZ)
Business
MetaStat, Inc. operates as a precision medicine company specializing in the research, development, and commercialization of therapeutic and diagnostic treatment solutions for cancer patients. The company primarily offers molecular diagnostic products focused on assessing the risk of systemic metastasis in epithelial-based solid tumors. Its key diagnostic platforms include MetaSite Breast, designed for early-stage invasive breast cancer patients, and MenaCalc, a tissue-based quantitative immunofluorescence assay applicable across a range of epithelial cancers such as breast, lung, colorectal, and prostate. These diagnostic tools provide oncologists with clinically actionable information regarding tumor aggressiveness and metastasis risk to guide adjuvant chemotherapy treatment decisions. Founded in 2009 and headquartered in Boston, Massachusetts, MetaStat targets the oncology healthcare market internationally. Recent major developments include ongoing efforts to advance the commercialization of its diagnostic product lines, placing emphasis on expanding the clinical adoption of MetaSite Breast and MenaCalc platforms. The company has maintained its strategic focus on precision oncology diagnostics to improve cancer patient outcomes by targeting critical metastatic pathways in solid tumors. While no recent acquisitions or funding rounds have been prominently reported in the last 1-2 years, MetaStat continues to enhance its molecular diagnostic technologies and engagement with scientific advisory boards to support its growth in precision medicine. Its business model revolves around delivering targeted, pathway-driven diagnostics to oncologists aimed at personalized cancer treatment decision-making. MetaStat’s operations encompass development and commercialization of novel cancer diagnostics, focusing on epithelial tumors with solid applications in breast and other common cancers. The company maintains a pipeline centered on refining and validating its assay platforms, supported by scientific advisory members and clinical researchers. MetaStat’s industry positioning highlights its specialization within the biotechnology and molecular diagnostics sectors, with an operational footprint oriented towards oncologists, hospitals, and diagnostic labs primarily in the United States but with potential international clinical reach. The company remains listed publicly with the ticker MTST. This description reflects MetaStat’s core business lines, key products, geographic and market focus, founding, headquarters, and the latest strategic business emphasis on diagnostic commercialization and precision oncology development as of 2025.

Company News

APIChatGPT

  • defenseworld.net

    Metastat (OTCMKTS:MTST) vs. SNDL (NASDAQ:SNDL) Head to Head Survey